Results 1 to 10 of about 133,413 (254)

Hepatitis B Vaccines. [PDF]

open access: yesJ Infect Dis, 2021
Abstract Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality.
Pattyn J   +3 more
europepmc   +5 more sources

Booster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection [PDF]

open access: yesVaccines
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV.
Julie Sejerøe-Olsen   +9 more
doaj   +2 more sources

The role of new hepatitis B vaccines in South Africa

open access: goldSouth African Medical Journal
Vaccination is key to eliminating hepatitis B virus infection in South Africa (SA). Despite introducing immunisation in 1995, as part of the expanded programme of immunisation (EPI), hepatitis B virus infection remains endemic, and EPI vaccine ...
G U van Zyl   +3 more
doaj   +3 more sources

HBV Vaccines: Advances and Development

open access: yesVaccines, 2023
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as ...
Faisal Mahmood   +9 more
doaj   +1 more source

Prevalence of protective antibody levels against hepatitis B infection among healthcare workers in a tertiary care hospital in India

open access: yesAsian Journal of Medical Sciences, 2023
Background: Hepatitis B virus (HBV) infection affects more than 2 billion individuals globally HBV. The chance of dying from liver cirrhosis, acute fulminant liver disease, or hepatocellular carcinoma (HCC) is present in 240 million of these chronic HBV ...
Ramesh Thanikachalam   +2 more
doaj   +1 more source

Neonatal hepatitis B vaccination: Reevaluating timing and adjuvants for enhanced safety and effectiveness

open access: yesPediatric Discovery, 2023
Our aim is an achievement of a 100 percent vaccination rate without toxic vaccine effects. We did a comprehensive literature review on aluminum neurotoxicity and early neonatal hepatitis B vaccination.
Aleksandar Cirovic   +3 more
doaj   +1 more source

EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA

open access: yesHematology, Transfusion and Cell Therapy, 2021
Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL
Elif KILIC KONTE   +4 more
doaj   +1 more source

METHODS FOR ASSESSMENT OF THE SPECIFIC ACTIVITY OF DRUGS FOR PREVENTION OF HEPATITIS B

open access: yesВопросы вирусологии, 2017
The immunologic activity (specific activity) is one of the main indicators of quality of vaccines for prophylaxis of hepatitis B, along with their safety.
E. L. Postnova   +3 more
doaj   +1 more source

Mandatory vaccinations in European countries, undocumented information, false news and the impact on vaccination uptake: the position of the Italian pediatric society. [PDF]

open access: yes, 2018
BACKGROUND: High rates of vaccination coverage are important in preventing infectious diseases. Enforcing mandatory vaccinations is one of the strategies that some Countries adopted to protect the community when vaccination coverage is not satisfactory ...
Bozzola E   +5 more
core   +2 more sources

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

open access: yes, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy